Immunocore is a privately owned biotechnology company focused on the development of engineered monoclonal T-cell Receptors (mTCRs) as the next evolutionary step after monoclonal antibodies.

Unlike conventional monoclonal antibodies, Immunocore’s mTCRs are not restricted to targeting cells via their membrane proteins. Instead, mTCRs use the power of the body’s own immune surveillance system, the T-Cell Receptor, as a means of targeting cells differentially expressing any protein, including intracellular ones. This platform technology opens up the ability of targeting cells based upon numerous known and well validated molecular targets unsuitable for monoclonal antibodies, thus removing a key bottleneck to the future development of effective biological therapeutics.

Immunocore is developing a broad platform of mTCR-based therapeutics for the treatment of a range of cancers, type I diabetes and HIV.